Loading...
XSWX
KURN
Market cap731mUSD
Apr 09, Last price  
16.40CHF
1D
-8.74%
1Q
-30.06%
Jan 2017
-8.75%
Name

Kuros Biosciences AG

Chart & Performance

D1W1MN
P/E
—
P/S
18.62
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.99%
Rev. gr., 5y
115.93%
Revenues
34m
+86.61%
4,112,0004,358,000724,00035,882,00019,723,0009,108,00022,349,0001,571,0001,100,0001,000,0001,000,0006,355,0001,061,000534,000715,0002,561,0004,039,00013,815,00017,986,00033,564,000
Net income
-14m
L-5.95%
-23,850,000-28,480,000-34,552,000-6,875,000-26,009,000-24,826,000-1,454,000-18,779,000-9,216,000-30,826,000-34,026,0006,227,000-19,744,000-16,484,000-11,693,000-11,252,000-11,520,000-7,541,000-14,595,000-13,727,000
CFO
-9m
L+20.36%
-22,682,000-27,078,000-28,674,000-4,398,000-27,895,000-15,248,000-4,685,000-8,807,000-11,537,000-19,170,000-23,758,000-2,514,000-8,893,000-10,678,000-12,838,000-10,849,000-9,239,000-5,453,000-7,348,000-8,844,000
Earnings
Apr 17, 2025

Profile

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
URL
http://www.kuros.ch/
IPO date
Oct 29, 2002
Employees
73
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
33,564
86.61%
17,986
30.19%
Cost of revenue
35,918
23,564
Unusual Expense (Income)
NOPBT
(2,354)
(5,578)
NOPBT Margin
Operating Taxes
380
(1,396)
Tax Rate
NOPAT
(2,734)
(4,182)
Net income
(13,727)
-5.95%
(14,595)
93.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
501
6,000
BB yield
-0.39%
-12.04%
Debt
Debt current
578
416
Long-term debt
3,708
3,410
Deferred revenue
Other long-term liabilities
(5,073)
Net debt
(14,364)
(71,288)
Cash flow
Cash from operating activities
(8,844)
(7,348)
CAPEX
(317)
(400)
Cash from investing activities
(326)
(400)
Cash from financing activities
(171)
3,224
FCF
(3,430)
(4,058)
Balance
Cash
14,208
24,065
Long term investments
4,442
51,049
Excess cash
16,972
74,215
Stockholders' equity
(16,587)
(91,699)
Invested Capital
75,442
157,399
ROIC
ROCE
EV
Common stock shares outstanding
36,582
33,901
Price
3.49
137.41%
1.47
-23.64%
Market cap
127,671
156.19%
49,834
-21.06%
EV
113,307
(21,454)
EBITDA
398
(2,744)
EV/EBITDA
284.69
7.82
Interest
186
4,317
Interest/NOPBT